Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Retifanlimab

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Unknown1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT03679767Phase 2Completed

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

NCT04839510Phase 2UnknownPrimary

A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Showing all 2 trials

Research Network

Common Treatments

  • Retifanlimab1
  • Mrg0021

Active Sponsors

  • Incyte Corporation1
  • Shanghai Miracogen Inc.1

Top Investigators

Related Conditions

  • Metastatic Clearcell Renal Cell Carcinoma1
  • Unresectable Melanoma1
  • Metastatic Nonsmall Cell Lung Cancer1
  • Metastatic Urothelial Cancer1
  • Metastatic Urothelial Carcinoma1

Activity Timeline